ENTA
Enanta Pharmaceuticals Inc
NASDAQ: ENTA · HEALTHCARE · BIOTECHNOLOGY
$13.87
+1.17% today
Updated 2026-04-29
Market cap
$386.25M
P/E ratio
—
P/S ratio
5.77x
EPS (TTM)
$-3.21
Dividend yield
—
52W range
$5 – $17
Volume
0.2M
Enanta Pharmaceuticals Inc (ENTA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-106.80%
Operating margin
-60.50%
ROE
-60.00%
ROA
-13.50%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2010 | $22.76M | $7.90M | 100.00% | 30.50% | 34.72% |
| 2011 | $41.88M | $23.31M | 100.00% | 60.41% | 55.66% |
| 2012 | $41.71M | $21.40M | 100.00% | 51.05% | 51.31% |
| 2013 | $32.05M | $9.63M | 100.00% | 28.17% | 30.03% |
| 2014 | $47.74M | $34.44M | 100.00% | 39.77% | 72.14% |
| 2015 | $160.88M | $78.99M | 100.00% | 77.17% | 49.10% |
| 2016 | $88.27M | $21.67M | 100.00% | 34.94% | 24.55% |
| 2017 | $102.81M | $17.71M | 100.00% | 23.94% | 17.23% |
| 2018 | $206.63M | $71.96M | 100.00% | 42.75% | 34.82% |
| 2019 | $205.20M | $46.38M | 100.00% | 17.90% | 22.60% |
| 2020 | $122.47M | $-36.17M | 100.00% | -34.00% | -29.53% |
| 2021 | $97.07M | $-79.00M | 100.00% | -112.88% | -81.38% |
| 2022 | $86.16M | $-121.75M | 100.00% | -143.74% | -141.31% |
| 2023 | $79.20M | $-133.82M | 100.00% | -173.23% | -168.95% |
| 2024 | $67.64M | $-116.05M | 100.00% | -179.92% | -171.58% |
| 2025 | $65.32M | $-81.89M | 92.98% | -130.65% | -125.36% |